200 related articles for article (PubMed ID: 22415798)
1. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
4. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
Tran NH; Foster NR; Mahipal A; Byrne T; Hubbard J; Silva A; Mody K; Alberts S; Borad MJ
Invest New Drugs; 2021 Aug; 39(4):1072-1080. PubMed ID: 33646489
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Han JY; Lee SH; Lee GK; Yun T; Lee YJ; Hwang KH; Kim JY; Kim HT
Cancer Chemother Pharmacol; 2015 Mar; 75(3):475-83. PubMed ID: 25552401
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
[TBL] [Abstract][Full Text] [Related]
9. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Molina AM; van der Mijn JC; Christos P; Wright J; Thomas C; Dutcher JP; Nanus DM; Tagawa ST; Gudas LJ
Invest New Drugs; 2020 Oct; 38(5):1383-1389. PubMed ID: 31898184
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA
Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
[TBL] [Abstract][Full Text] [Related]
17. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Maroto JP; del Muro XG; Mellado B; Perez-Gracia JL; Andrés R; Cruz J; Gallardo E; Domenech M; Arranz JA; Meana JA
Clin Transl Oncol; 2013 Sep; 15(9):698-704. PubMed ID: 23359179
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
